The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
REVANCE THERAPEUTICS, INC. | COM | 761330109 | 42,779 | 1,558,426 | SH | DFND | 2, 3, 4 | 0 | 0 | 1,558,426 | |
MYOVANT SCIENCES LTD. | COM | G637AM102 | 24,014 | 1,050,000 | SH | DFND | 2, 3, 4 | 0 | 0 | 1,050,000 | |
MYOVANT SCIENCES LTD. | COM | G637AM102 | 3,146 | 138,361 | SH | DFND | 0 | 0 | 138,361 |